Gerresheimer: Business performance and slower market growth require guidance adjustment

EQS-News: Gerresheimer AG / Key word(s): Profit Warning/Quarter Results Gerresheimer: Business performance and slower market growth require guidance adjustment 08.10.2025 / 23:58 CET/CEST The issuer is solely responsible for the content of this announcement. Gerresheimer: Business performance and slower market growth require guidance adjustment

• Preliminary results for 9M 2025: Revenues +14.6%, Adjusted EBITDA +7.2% 
• Organic development: Revenues -1.8%, Adjusted EBITDA -7.5%
• Subdued demand in the cosmetics and oral liquids segment continues
• Separation of Moulded Glass progressing according to plan; independent division within new segmentation from 2026
• Updated guidance for 2025: Organic revenue decline of -2% to -4%, adjusted EBITDA margin around 18.5 to 19%
• Transformation program initiated to increase performance and reduce costs

Duesseldorf, October 8, 2025. Gerresheimer, an innovative system and solution provider and global partner for the pharma, biotech, and cosmetics industries, is adjusting its guidance for the 2025 financial year in light of the preliminary results for the third quarter of 2025 and slower-than-expected market growth. According to preliminary figures, revenues in the third quarter of 2025 declined organically by -1.2% compared to the same period last year, with an organic adjusted EBITDA margin of 18.8%. According to preliminary results, Gerresheimer generated positive free cash flow of EUR 21 million in the third quarter of 2025. Revenue growth and the adjusted EBITDA margin for the first nine months of the 2025 financial year are lower than expected overall. Although the company expects the fourth quarter to be stronger than the third quarter due to production ramp-ups for drug delivery systems, revenues for the full year 2025 are now expected to decline organically between -4% and -2% (previously organic revenue growth 0 to 2%), and the adjusted EBITDA margin is expected to be around 18.5% to 19% (previously around 20%). In the first nine months of the 2025 financial year, preliminary figures show that revenues rose by 14.6% to EUR 1,681.4 million (9M 2024: EUR 1,467.0 million), while adjusted EBITDA rose by 7.2% to EUR 313.9 million (9M 2024: EUR 292.7 million). Organic development compared with the pro forma figures for the same period last year continued to show significant market influences, including subdued demand in the cosmetics market and in the area of containment solutions for oral liquids. According to preliminary results, organic revenues declined by 1.8% in the first nine months, while adjusted EBITDA fell by 7.5%. The organic adjusted EBITDA margin was 18.8% (9M 2024: 19.9%). In view of slower market growth and business development in 2025, Gerresheimer has initiated a transformation program to reduce costs and improve performance.